5-(tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK1 receptor antagonists:: Structure-activity relationship studies on the substituent at N2-position

被引:12
|
作者
Bartolomé-Nebreda, JM
Patiño-Molina, R
Martín-Martínez, M
Gómez-Monterrey, I
García-López, MT
González-Muñiz, R
Cenarruzabeitia, E
Latorre, M
Del Río, J
Herranz, R
机构
[1] CSIC, Inst Quim Med, E-28006 Madrid, Spain
[2] Univ Navarra, Dept Farmacol, E-31080 Pamplona, Spain
关键词
D O I
10.1021/jm010813d
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
To establish structure-activity relationships a new series of analogues of the highly potent and selective CCK1 receptor antagonist (4aS,5R)-2-benzyl-5-(N-Boc-tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]-pyrimidine (1a) modified at N2-position of the central scaffold has been prepared and evaluated as CCK receptor ligands. With this aim the N2-benzyl group has been replaced by methyl, cyclohexyl, aromatic groups, 1-phenylethyl, and 1-carboxy-2-phenylethyl group. Then, substituents with different electronic and steric properties were introduced into different positions of the phenyl group of analogues 19a and 19b. The results of the CCK receptor binding and in vitro functional activity evaluation suggest the importance of the lipophilic character and an appropriate spatial orientation of the moiety linked at the N2-position of the 1,3-dioxoperhydropyrido[1,2-c]pyrimidine template for potent and selective binding and antagonist activity at CCK1 receptor subtype. The 2-cyclohexyl and (2S)-1-naphthyl derivatives 18a and (2S)-20a have emerged as more potent and selective CCK1 receptor antagonists than the lead compound 1a. Additionally, the results confirm the (4aS,5R)stereochemistry at the central bicyclic skeleton as an essential structural requirement for potent binding to this receptor subtype.
引用
收藏
页码:2219 / 2228
页数:10
相关论文
共 26 条
  • [1] 5-(tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c] pyrimidine-based potent and selective CCK1 receptor antagonists:: Structure-activity relationship studies on the central 1,3-dioxoperhydropyrido[1,2-c]pyrimidine scaffold
    Bartolomé-Nebreda, JM
    García-López, MT
    González-Muñiz, R
    Cenarruzabeitia, E
    Latorre, M
    Del Río, J
    Herranz, R
    JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (24) : 4196 - 4206
  • [2] 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK1 receptor antagonists:: Structural modifications at the tryptophan domain
    Bartolomé-Nebreda, JM
    Gómez-Monterrey, I
    García-López, MT
    González-Muñiz, R
    Martín-Martínez, M
    Ballaz, S
    Cenarruzabeitia, E
    LaTorre, M
    Del Río, J
    Herranz, R
    JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (22) : 4659 - 4668
  • [3] 5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists:: Reversal of CCK1 receptor subtype selectivity toward CCK2 receptors
    Muñoz-Ruiz, P
    García-López, MT
    Cenarruzabeitia, E
    Del Río, J
    Dufresne, M
    Foucaud, M
    Fourmy, D
    Herranz, R
    JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (21) : 5318 - 5329
  • [4] Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivations: Potent and selective cholecystokinin-A receptor antagonists
    MartinMartinez, M
    BartolomeNebreda, JM
    GomezMonterrey, I
    GonzalezMuniz, R
    GarciaLopez, MT
    Ballaz, S
    Barber, A
    Fortuno, A
    DelRio, J
    Herranz, R
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (21) : 3402 - 3407
  • [5] Structure-activity relationship studies of imidazo[1,2-c] pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors
    Hirabayashi, Akihito
    Mukaiyama, Harunobu
    Kobayashi, Hiroaki
    Shiohara, Hiroaki
    Nakayama, Satoko
    Ozawa, Motoyasu
    Tsuji, Eiichi
    Miyazawa, Keiji
    Misawa, Keiko
    Ohnota, Hideki
    Isaji, Masayuki
    BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (20) : 9247 - 9260
  • [6] Structure-activity relationship studies of 5-benzylaminoimidazo[1,2-c]pyrimidine-8-carboxamide derivatives as potent, highly selective ZAP-70 kinase inhibitors
    Hirabayashi, Akihito
    Mukaiyama, Harunobu
    Kobayashi, Hiroaki
    Shiohara, Hiroaki
    Nakayama, Satoko
    Ozawa, Motoyasu
    Miyazawa, Keiji
    Misawa, Keiko
    Ohnota, Hideki
    Isaji, Masayuki
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (01) : 284 - 294
  • [7] Synthesis and structure-activity relationship of a new series of potent AT(1) selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles
    Almansa, C
    Gomez, LA
    Cavalcanti, FL
    deArriba, AF
    GarciaRafanell, J
    Forn, J
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (04) : 547 - 558
  • [8] CoMFA methodology in structure-activity analysis of hexahydro- and octahydropyrido[1,2-c]pyrimidine derivatives based on affinity towards 5-HT1A, 5-HT2A and α1-adrenergic receptors
    Maciejewska, Dorota
    Zolek, Teresa
    Herold, Franciszek
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2006, 25 (03): : 353 - 362
  • [9] Naphtho[1,2-b][1,4]diazepinedione-Based P2X4 Receptor Antagonists from Structure-Activity Relationship Studies toward PET Tracer Development
    Erlitz, Katharina Sophie
    Prinz, Ann-Kathrin
    Wagner, Stefan
    Massa, Joana
    Dunker, Calvin
    Hoehl, Meike
    Griep, Angelika
    Mcmanus, Roisin M.
    Schelhaas, Sonja
    Koch, Oliver
    Junker, Anna
    JOURNAL OF MEDICINAL CHEMISTRY, 2025,
  • [10] Therapeutic potentials and structure-activity relationship of 1,3-benzo-dioxole N-carbamothioyl carboxamide derivatives as selective and potent antagonists of P2X4 and P2X7 receptors
    Mahmood, Abid
    Villinger, Alexander
    Iqbal, Jamshed
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 238